The effect of somatostatin analogues on Ki-67 levels in GH-secreting adenomas

SELEK A., Cetinarslan B., CANTÜRK Z., Tarkun I., HANAZAY Y., VURAL Ç., ...More

GROWTH HORMONE & IGF RESEARCH, vol.45, pp.1-5, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 45
  • Publication Date: 2019
  • Doi Number: 10.1016/j.ghir.2019.01.001
  • Journal Name: GROWTH HORMONE & IGF RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1-5
  • Keywords: Somatostatin analogue, Ki-67, GH-secreting adenomas, Acromegaly, PREOPERATIVE OCTREOTIDE TREATMENT, TUMOR VOLUME, EXPRESSION, APOPTOSIS, CONSENSUS, CRITERIA, THERAPY, MARKER
  • Kocaeli University Affiliated: Yes

Abstract

Purpose: Somatostatin analogues (SSAs) can slow down the growth of neuroendocrine tumors. However, the mechanism remains unclear. Recent studies on patients with acromegaly suggest that SSAs may induce apoptosis, increase autophagy, and decrease cell proliferation of pituitary adenoma. Ki-67-labeling index is a marker of cellular proliferation; therefore, decreased levels are associated with inhibition of proliferation. The aim of this study was to evaluate and compare the Ki-67-labeling index of GH-secreting pituitary adenoma tissues in patients who had undergone pituitary surgery twice due to residual or recurrent tumors and had received SSA treatment between the two surgeries.